Donald J. Garcia, Jr., MD, PA

Austin, Texas 78737

0 studies enrolling now · 16 studies all time

What they study most

Acute Migraine, Anhedonia, Depressive Disorder, Major, Major Depressive Disorder, Migraine, Obsessive-Compulsive Disorder, Schizophrenia, Stress Disorders, Post-Traumatic

Studies at this site

• A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder — Completed
• A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder — Running, not enrolling
• Zelquistinel in the Treatment of Major Depressive Disorder — Completed
• A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive Disorder — Completed
• A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy — Completed
• A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine — Completed
• A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder — Completed
• Study To Evaluate The Efficacy And Safety Of Balovaptan In Adults With Post-Traumatic Stress Disorder (PTSD) — Completed
• A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia — Completed
• Randomized Trial in Adult Participants With Acute Migraines — Completed
• Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD) — Stopped early
• Study of Rapastinel as Monotherapy in Patients With MDD — Stopped early
• Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD) — Stopped early
• Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder — Completed
• A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder — Completed
• A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01) — Completed